This CPB has been revised to state that leuprolide is considered medically necessary for treatment of relapsed granulosa cell tumors of the ovary. This policy revision is based upon guidelines from the National Comprehensive Cancer Network. This CPB is revised to state that leuprolide is considered medically necessary for treatment-resistant paraphilias. This CPB is revised to state that leuprolide is experimental and investigational for the treatment of epilepsy as well as Alzheimer's disease.